Success Metrics

Clinical Success Rate
80.8%

Based on 42 completed trials

Completion Rate
81%(42/52)
Active Trials
3(5%)
Results Posted
45%(19 trials)
Terminated
10(15%)

Phase Distribution

Ph phase_3
9
14%
Ph early_phase_1
1
2%
Ph phase_2
18
27%
Ph phase_1
10
15%
Ph not_applicable
12
18%
Ph phase_4
13
20%

Phase Distribution

11

Early Stage

18

Mid Stage

22

Late Stage

Phase Distribution63 total trials
Early Phase 1First-in-human
1(1.6%)
Phase 1Safety & dosage
10(15.9%)
Phase 2Efficacy & side effects
18(28.6%)
Phase 3Large-scale testing
9(14.3%)
Phase 4Post-market surveillance
13(20.6%)
N/ANon-phased studies
12(19.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

77.8%

42 of 54 finished

Non-Completion Rate

22.2%

12 ended early

Currently Active

3

trials recruiting

Total Trials

66

all time

Status Distribution
Active(3)
Completed(42)
Terminated(12)
Other(9)

Detailed Status

Completed42
Terminated10
unknown9
Active, not recruiting2
Withdrawn2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
66
Active
3
Success Rate
80.8%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (1.6%)
Phase 110 (15.9%)
Phase 218 (28.6%)
Phase 39 (14.3%)
Phase 413 (20.6%)
N/A12 (19.0%)

Trials by Status

active_not_recruiting23%
recruiting12%
completed4264%
terminated1015%
unknown914%
withdrawn23%

Recent Activity

Clinical Trials (66)

Showing 20 of 66 trialsScroll for more
NCT05477576Phase 3

Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

Recruiting
NCT06865677Phase 2

Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas

Terminated
NCT03624517Phase 4

Comparison of 24-hours Versus 72-hours of Octreotide Infusion in Preventing Early Rebleed From Esophageal Varices

Terminated
NCT00262470Phase 1

Treatment of Orthostatic Intolerance

Active Not Recruiting
NCT03000946Phase 3

Prevention of Postoperative Pancreatic Fistula by Somatostatin

Completed
NCT06193616

Outcome of ADPKD With Octreotide LAR

Active Not Recruiting
NCT03289741Phase 4

A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide

Completed
NCT02457156Phase 3

Cattell-Warren Versus Blumgart Techniques of Pancreatico-jejunostomy Following Pancreato-duodenectomy

Completed
NCT00463983Phase 1

Treatment of Idiopathic Pulmonary Fibrosis with Long Acting Octreotide

Completed
NCT04048707Phase 2

Angiotensin 2 for Hepatorenal Syndrome

Withdrawn
NCT03179995Phase 2

Trial Using Octreotide to Enhance Liver Recovery After Hepatectomy

Terminated
NCT02385617Not Applicable

Food Intake and Gut Hormones in Patients Who Have Undergone Upper Gastrointestinal Surgery for Cancer

Completed
NCT02381249Not Applicable

The Effect of Satiety Gut Hormone Modulation on Appetitive Drive After Upper Gastrointestinal Surgery

Completed
NCT06085976Phase 2

Efficacy and Safety of Octreotide in Laparoscopic Hepatectomy Surgery: Effect on Blood Loss, Need for Vasoactive Drugs, Transfusion Requirements.

Unknown
NCT00427349Phase 2

AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors

Completed
NCT02333565Phase 2

Combination of Everolimus and Octreotide LAR in Aggressive Recurrent Meningiomas

Completed
NCT02384122Phase 3

Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias

Completed
NCT01613495Not Applicable

Ghrelin Suppression by Octreotide in Prader-Willi

Unknown
NCT04027348Phase 2

Palliative Management of Inoperable Malignant Bowel Obstruction

Terminated
NCT02010385Not Applicable

Investigation of the Effects of Obesity Surgery on Appetitive Behaviour

Completed

Drug Details

Intervention Type
DRUG
Total Trials
66